Evidence map›Paper›PMID 26065636›Full record

ArticleGlobal health action2015

Are long-lasting insecticide-treated bednets and water filters cost-effective tools for delaying HIV disease progression in Kenya?

Stéphane Verguet, James G Kahn, Elliot Marseille, Aliya Jiwani, Eli Kern, Judd L Walson

Open access · goldAbstract read
In one paragraph

Article in Global health action, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Stéphane VerguetDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA; verguet@hsph.harvard.edu.
James G KahnPhilip R. Lee Institute for Health Policy Studies, University of California, San Francisco, CA, USA.
Elliot MarseilleHealth Strategies International, Oakland, CA, USA.
Aliya JiwaniHealth Strategies International, Arlington, VA, USA.
Eli KernAssessment, Policy Development & Evaluation, Public Health-Seattle & King County, WA, USA.
Judd L WalsonDepartment of Global Health, University of Washington, Seattle, WA, USA.
Global Brain Health Institute · USHarvard Global Health Institute · USInstitute for Global Environmental Strategies · USPublic Health – Seattle & King County · USUniversity of Washington · US

Funding

Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR01DA015612 · NIDA · STANFORD UNIVERSITY · PI OWENS, DOUGLAS K · 2002 to 2017
$9.4M
Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR37DA015612 · NIDA · STANFORD UNIVERSITY · PI DOUGLAS K OWENS · 2019 to 2026
$6.3M
NIDA NIH HHS R01 DA015612NIDA NIH HHS R37 DA015612
6 · The paper itself

Abstract

backgroundCo-infection with malaria and other infectious diseases has been shown to increase viral load and accelerate HIV disease progression. A recent study in Kenya demonstrated that providing long-lasting insecticide-treated bednets (LLIN) and water filters (WF) to HIV-positive adults with CD4 >350 cells/mm(3) significantly reduced HIV progression.

designWe conducted a cost analysis to estimate the potential net financial savings gained by delaying HIV progression and increasing the time to antiretroviral therapy (ART) eligibility through delivering LLIN and WF to 10% of HIV-positive adults with CD4 >350 cells/mm(3) in Kenya.

resultsGiven a 3-year duration of intervention benefit, intervention unit cost of US$32 and patient-year ART cost of US$757 (2011 US$), over the lifetime of ART patients, in Kenya, we estimated the intervention could yield a return on investment (ROI) of 11 (95% uncertainty range [UR]: 5-23), based on a cost of about US$2 million and savings in ART costs of about US$26 million (95% UR: 8-50) (discounted at 3%). Our findings were subjected to a number of sensitivity analyses. Of note, deferral of time to ART eligibility could potentially result in 3,000 new HIV infections not averted by ART and thus decrease ART cost savings to US$14 million, decreasing the ROI to 6.

conclusionsProvision of LLIN and WF could be a cost-saving and practical method to defer time to ART eligibility in the context of highly resource-constrained environments experiencing donor fatigue for HIV/AIDS programs.

Indexed as

CD4 Lymphocyte CountCoinfectionCost-Benefit AnalysisDisease ProgressionHIV InfectionsHumansInsecticide-Treated BednetsKenyaMalariaModels, EconometricReproducibility of ResultsViral LoadWater Supplyantiretroviral therapycost savingsdiarrheaHIV disease progressioninsecticide-treated bednetsKenyamalariasub-Saharan Africawater filtration

Identifiers

PMID26065636
PMCPMC4463495
OpenAlexW1853962065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.